2cb941c66b336d4f…

{
  "id": "NCT00056524",
  "type": "Study",
  "data": {
    "briefSummary": "The purpose of this study is to evaluate the long-term safety of AVP-923 in the treatment of Involuntary Emotional Expression Disorder (IEED) also known as Pseudobulbar Affect (episodes of uncontrolled crying and/or laughter).",
    "completionDate": "2007-06",
    "conditions": [
      "Alzheimer's Disease",
      "Stroke",
      "Parkinson's Disease",
      "Traumatic Brain Injury"
    ],
    "enrollmentCount": 600,
    "enrollmentType": "ESTIMATED",
    "nctId": "NCT00056524",
    "phase": "PHASE3",
    "sponsorId": "avanir-pharmaceuticals",
    "startDate": "2003-02",
    "status": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "title": "An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.",
    "url": "https://clinicaltrials.gov/study/NCT00056524"
  }
}